Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AIC100 |
| Synonyms | |
| Therapy Description |
AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AIC100 | AIC-100|AIC 100 | AIC100 is a cell therapy consisting of T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the intercellular adhesion molecule-1 (ICAM-1), and CD28, potentially leading to activation of inhibitory T cells, inhibition of cell proliferation and inhibition of tumor growth (PMID: 31337787, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04420754 | Phase I | AIC100 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Active, not recruiting | USA | 0 |